title: Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?
abstract: Central nervous system (CNS) involvement from breast cancer (BC) has been historically considered a relatively rare event. However, the development of new therapeutic strategies with a better control of extra-cranial disease and a longer overall survival (OS) has determined an increased incidence of brain metastases. Patients with HER2-positive or triple negative BC have higher occurrence of CNS involvement than patients with luminal-like disease. Moreover, after development of brain metastases, the prognosis is highly influenced by biological subtype. In patients with multiple brain metastases who experience important neurological symptoms, palliative treatment, with or without whole brain radiation therapy (WBRT), needs to be considered the first step of a multidisciplinary therapeutic approach. Patients with a good performance status and 1-3 brain lesions should be considered for radical surgery; patients technically inoperable with 4-5 metastases smaller than 3cm may undergo stereotactic radiosurgery. The role of systemic therapy in the management of patients with brain metastases is controversial. Preliminary data suggest that systemic therapy after WBRT may improve survival in BC patients with brain lesions. In patients with HER2-positive disease, several retrospective or post hoc analyses showed a longer brain progression-free survival with trastuzumab in combination with or followed by other anti-HER2 drugs (such as pertuzumab, lapatinib, and T-DM1). Until now, no new strategies or drugs are available for triple-negative and luminal-like BC.
authors.affiliation: Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Italy.
authors.forename: Caterina
authors.initials: C
authors.lastname: Fontanella
authors.affiliation: Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: De Carlo
authors.affiliation: Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Italy.
authors.forename: Marika
authors.initials: M
authors.lastname: Cinausero
authors.affiliation: Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Italy.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Pelizzari
authors.affiliation: Department of Medical and Biological Science, University of Udine, Udine, Italy.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Venuti
authors.affiliation: Department of Medical and Biological Science, University of Udine, Udine, Italy; Department of Oncology, University Hospital of Udine, Italy. Electronic address: fabio.puglisi@uniud.it.
authors.forename: Fabio
authors.initials: F
authors.lastname: Puglisi
mesh_terms: D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D014916:Whole-Body Irradiation
keywords: Breast cancer subtypes; Central nervous system involvement; Locoregional and systemic treatment; Metastatic breast cancer